FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.

CONTEXT Parenteral iron administration has been associated with hypophosphatemia. Fibroblast growth factor 23 (FGF23) has a physiological role in phosphate homeostasis via suppression of 25-hydroxyvitamin D [25(OH)D] activation and promotion of phosphaturia. We recently reported a case of iron-induced hypophosphatemic osteomalacia associated with marked FGF23 elevation. OBJECTIVE Our objective was to prospectively investigate the effect of parenteral iron polymaltose on phosphate homeostasis and to determine whether any observed change was related to alterations in circulating FGF23. DESIGN, SETTING, AND PARTICIPANTS Eight medical outpatients prescribed iv iron polymaltose were recruited. Plasma phosphate, 25(OH)D, 1,25-dihydroxyvitamin D [1,25(OH)(2)D], PTH, FGF23, and urinary tubular reabsorption of phosphate were measured prior to iron administration and then weekly for a minimum of 3 wk. RESULTS Plasma phosphate fell from 3.4 +/- 0.6 mg/dl at baseline to 1.8 +/- 0.6 mg/dl at wk 1 (P < 0.0001) associated with a fall in percentage tubular reabsorption of phosphate (90 +/- 4.8 to 68 +/- 13; P < 0.001) and 1,25(OH)(2)D (54 +/- 25 to 9 +/- 8 pg/ml; P < 0.001). These indices remained significantly suppressed at wk 2 and 3. 25(OH)D levels were unchanged. FGF23 increased significantly from 43.5 pg/ml at baseline to 177 pg/ml at wk 1 (P < 0.001) with levels correlating with both serum phosphate (R = -0.74; P <0.05) and 1,25(OH)(2)D (R = -0.71; P < 0.05). CONCLUSION Parenteral iron suppresses renal tubular phosphate reabsorption and 1alpha-hydroxylation of vitamin D resulting in hypophosphatemia. Our data suggest that this is mediated by an increase in FGF23.

[1]  M. Doogue,et al.  Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia , 2009, Annals of clinical biochemistry.

[2]  M. Razzaque,et al.  Genetic Evidence of Serum Phosphate-Independent Functions of FGF-23 on Bone , 2008, PLoS genetics.

[3]  D. Coyne,et al.  Intravenous iron: From anathema to standard of care , 2008, American journal of hematology.

[4]  J. Aubin,et al.  Overexpression of Fibroblast Growth Factor 23 Suppresses Osteoblast Differentiation and Matrix Mineralization In Vitro , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  R. Labianca,et al.  Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Mohammadi,et al.  The parathyroid is a target organ for FGF23 in rats. , 2007, The Journal of clinical investigation.

[7]  W. Fraser,et al.  The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays , 2007, Annals of clinical biochemistry.

[8]  G. Rodgers,et al.  Intravenous iron [25] , 2007 .

[9]  M. Razzaque,et al.  The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. , 2007, The Journal of endocrinology.

[10]  Shinzo Tanaka,et al.  α-Klotho as a Regulator of Calcium Homeostasis , 2007, Science.

[11]  M. Collins,et al.  Determination of the elimination half-life of fibroblast growth factor-23. , 2007, The Journal of clinical endocrinology and metabolism.

[12]  J. Glaspy,et al.  Clinical update: intravenous iron for anaemia , 2007, The Lancet.

[13]  Siu L. Hui,et al.  FGF23 Concentrations Vary With Disease Status in Autosomal Dominant Hypophosphatemic Rickets , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  Xi Jiang,et al.  Pathogenic role of Fgf23 in Hyp mice. , 2006, American journal of physiology. Endocrinology and metabolism.

[15]  M. Econs,et al.  Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. , 2006, The Journal of clinical endocrinology and metabolism.

[16]  L. Weinstein,et al.  Fibroblast Growth Factor‐23 Is Regulated by 1α,25‐Dihydroxyvitamin D , 2005 .

[17]  A. Meinders,et al.  Hypophosphatemia: an update on its etiology and treatment. , 2005, The American journal of medicine.

[18]  M. Econs,et al.  Fibroblast growth factor 23: roles in health and disease. , 2005, Journal of the American Society of Nephrology : JASN.

[19]  Tomas Ganz,et al.  Hepcidin--a regulator of intestinal iron absorption and iron recycling by macrophages. , 2005, Best practice & research. Clinical haematology.

[20]  R. Kumar,et al.  "Phosphatonins" and the regulation of phosphorus homeostasis. , 2005, American journal of physiology. Renal physiology.

[21]  Olivier Barbier,et al.  Effect of Heavy Metals on, and Handling by, the Kidney , 2005, Nephron Physiology.

[22]  R. Rizzoli,et al.  Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. , 2005, The Journal of clinical endocrinology and metabolism.

[23]  S. Kato,et al.  Circulating FGF-23 Is Regulated by 1α,25-Dihydroxyvitamin D3 and Phosphorus in Vivo* , 2005, Journal of Biological Chemistry.

[24]  M. Iida,et al.  Hypophosphatemia induced by intravenous administration of saccharated iron oxide , 1983, Klinische Wochenschrift.

[25]  M. Econs,et al.  FGF-23 is elevated by chronic hyperphosphatemia. , 2004, The Journal of clinical endocrinology and metabolism.

[26]  M. Auerbach,et al.  Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. White,et al.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. , 2003, The Journal of clinical investigation.

[28]  Amy Y. M. Au,et al.  Fibroblast Growth Factor 23: A New Clinical Marker for Oncogenic Osteomalacia , 2003 .

[29]  L. Quarles,et al.  Serum FGF23 Levels in Normal and Disordered Phosphorus Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  K. White,et al.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.

[31]  M. Levine,et al.  Molecular pathogenesis of hypophosphatemic rickets. , 2002, The Journal of clinical endocrinology and metabolism.

[32]  H. Murer,et al.  Proximal tubular phosphate reabsorption: molecular mechanisms. , 2000, Physiological reviews.

[33]  M. Shiraki,et al.  Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. , 1998, Endocrine journal.

[34]  T. Kobayashi,et al.  Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules. , 1997, Bone.

[35]  照雄 尾前,et al.  Saccharated ferric oxideの長期経静脈投与によつて骨軟化症を合併した非特異性多発性小腸潰瘍症の2例 , 1982 .

[36]  M. Murakami,et al.  [2 cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide]. , 1982, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[37]  R. DeFronzo,et al.  The effects of glucose and insulin on renal electrolyte transport. , 1976, The Journal of clinical investigation.

[38]  R. Pain,et al.  Hypophosphataemia and Hyperphosphataemia in a Hospital Population , 1972, British medical journal.

[39]  A. Relman,et al.  The effect of eating on some of the clinically important chemical constituents of the blood. , 1959, American journal of clinical pathology.

[40]  J. Nissim.  Intravenous Iron , 1954, Nutrition reviews.